FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Published: | Updated:
Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Approval Alert | Treosulfan/Fludarabine Injection for HSCT Conditioning in AML/MDS
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5